Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2018-01-17

Clinical Trial Update: Pharmacokinetic and Efficacy Profile Intranasal Scopolamine Spray [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial of intranasal scopolamine spray for motion sickness was terminated; results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • in nasal scopolamine spray (scopolamine)

Snippet

Sponsor: Repurposed Therapeutics, Inc. | Conditions: Motion Sickness | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2018-01-17